GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference

Trending Topics in Gastroenterology

Explore current gastroenterology questions, clinical answers, and emerging research by topic.

111

MORPHEUS-PDAC Umbrella Trial: The Oncologist | April 2026

Introduction Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with a 5-year survival of only 10–13%. A major biological challenge is its “cold tumor” microenvironment—characterized...

112

Duloxetine for Prevention of Oxaliplatin-Induced Neuropathy (OIPN): JCO Oncology Advances | April 2026

Introduction Oxaliplatin-induced peripheral neuropathy (OIPN) is a common, dose-limiting toxicity in colorectal cancer treatment, significantly impacting quality of life and long-term functional outcomes. Duloxetine, already proven effective for...

113

Subcutaneous Pembrolizumab: Journal of Clinical Oncology | April 2026

Introduction Immune checkpoint inhibitors like Pembrolizumab have transformed oncology care across multiple solid tumours. Recently, a subcutaneous (SC) formulation has been introduced using hyaluronidase technology, promising faster administration,...

114

FOLFIRINOX in Digestive NEC: J of Neuroendocrinology | April 2026

Introduction Digestive neuroendocrine carcinomas (NEC) are rare but highly aggressive malignancies with poor prognosis and limited therapeutic options. Standard first-line therapy consists of platinum plus etoposide, extrapolated from...

115

Tumour Location in Resected Pancreatic Cancer: AJS | April 2026

Introduction Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with survival rates rarely exceeding 10% at 5 years despite advances in surgery and systemic therapy....

116

Top 10 GI Oncology Updates: Oncology News/ March 2026

ESOPEC Trial (Oesophagal Cancer) Neoadjuvant chemoradiotherapy may have underperformed due to radiotherapy quality issues (e.g., lymphopenia). Do not abandon the CROSS approach yet—patient selection remains key. ORCHESTRA Trial...

117

Atezolizumab + FOLFOX in Stage III CRC: NEJM| March 2026

Introduction Stage III colon cancer is traditionally treated with adjuvant oxaliplatin-based chemotherapy such as FOLFOX. However, tumours with mismatch repair deficiency (dMMR) represent a biologically distinct subgroup with...

118

Adjuvant Therapy After Neoadjuvant Treatment in Resected Pancreatic Ann of Surg Onco — March 2026

Introduction The management of pancreatic ductal adenocarcinoma (PDAC) has increasingly shifted toward the use of neoadjuvant therapy (NAT) before surgical resection. NAT aims to improve resectability, treat micrometastatic...

119

First-Line Chemotherapy and Durvalumab in Advanced BTC: Oncology Advances — March 2026

Patients with advanced biliary tract cancer (BTC) often have limited life expectancy, making quality of life and time spent receiving medical care (“time toxicity”) important considerations when selecting...

120

Quality of Life vs Survival in Older Adults With Advanced Cancer Source: JAMA Oncology, March 2026

Introduction Treatment decisions in advanced cancer often involve a balance between extending survival and preserving quality of life (QoL). Older adults frequently face complex choices because aggressive treatments...

Previous
111121320
Next
GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer